DRMADermata Therapeutics, Inc.

Nasdaq dermatarx.com


$ 2.21 $ -0.16 (-6.75 %)    

Wednesday, 07-Aug-2024 15:51:13 EDT
QQQ $ 434.88 $ -10.70 (-2.4 %)
DIA $ 387.79 $ -2.17 (-0.56 %)
SPY $ 518.50 $ -9.29 (-1.76 %)
TLT $ 95.87 $ -0.17 (-0.18 %)
GLD $ 220.55 $ -0.15 (-0.07 %)
$ 2.37
$ 2.33
$ 2.31 x 100
-- x --
$ 2.17 - $ 2.33
$ 1.29 - $ 21.60
436,118
na
1.05M
$ -17.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 02-21-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-28-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 09-27-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 dermata-therapeutics-entered-into-atm-agreement-with-hc-wainwright-providing-for-sale-by-co-of-12m-of-its-shares-of-common-stock-from-time-to-time

- Reuters 

 dermata-therapeutics-on-june-4-got-letter-from-nasdaq-that-company-has-regained-compliance-with-minimum-bid-price-requirement

-SEC Filing

Core News & Articles

Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnolog...

 dermata-therapeutics-q1-2024-gaap-eps-047-misses-036-estimate

Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION